Why Is SAREPTA THERAPEUTICS (SRPT) Stock Down Today?

Why SRPT stock is down today

Sarepta Therapeutics (SRPT) fell 6.81% to $20.52 in afternoon trading after opening near $21.96. The decline followed a broader selloff in the biotech sector triggered by a failed clinical trial from Novartis, which weighed on investor sentiment for muscle disease drug developers. The stock’s intraday low of $20.52 was reached at 11:40 AM ET, with volume remaining muted at 0.5 million shares traded so far.

What Happened

Sarepta’s stock had previously rebounded from a recent slide, climbing 8% earlier in the week as the broader biotech sector experienced a short-term bounce. However, renewed concerns emerged after a clinical setback from Novartis, a key competitor in the space, caused a ripple effect across related stocks. H.C. Wainwright reissued its Sell rating on Sarepta with a $5 price target, reinforcing bearish sentiment. The stock’s decline came despite a generally positive market backdrop, where other sectors and stocks, including Caleres and iSpecimen, saw gains.

What The Data Shows

Sarepta’s fundamentals remain weak, with a trailing twelve-month (TTM) revenue decline of 20.4%, a net margin of -6.9%, and an unprofitable EPS of -1.32. The stock has traded between $14.68 and $25.32 over the past 52 weeks. Intraday volume remains low, at just 0.1 times the 3-month average. The stock has printed 19 fresh 52-week lows in recent sessions, and its price trend over the last 8 sessions was a modest gain of 6.1% from $20.86 to $22.13. No unusual options activity or insider filings have been reported in the last 90 days.

What To Watch

Sarepta Therapeutics does not have a scheduled earnings date in the near term. Investors should monitor the broader biotech sector for further reactions to clinical developments and any changes in analyst coverage.